Viewing entries tagged
Active Surveillance

Helpline Frequently Asked Questions

Comment

Helpline Frequently Asked Questions

PCRI's free Helpline connects patients and caregivers with educational advocates and helps them understand their personal case. This article is a top ten frequently asked questions list that our Helpline receives. 

Comment

Jevtana and Provenge

Comment

Jevtana and Provenge

New prostate cancer drugs come to market quite rarely because the studies mandated by the FDA cost hundreds of millions of dollars. The FDA requires these studies to randomly allocate men into two comparison groups. One group receives the new medicine being tested. The other group gets an ineffective fake, called a placebo. Assuming the study is performed in an acceptable manner, the FDA will approve a new drug for commercial use, only if the men who are receiving the new medicine outlive those treated with the placebo by a specified margin without excessive toxicity.

Comment

Three Rules in Prostate Cancer Treatment Decision

Comment

Three Rules in Prostate Cancer Treatment Decision

Selecting a treatment for prostate cancer is increasingly complex. In an effort to help my prostate cancer patients navigate the complexities of this process, I routinely frame the discussion around these three rules:

Rule #1: If you listen to enough people you will hear just about anything.

 

Comment